Research programme: prostate cancer antibodies - ImmunexAlternative Names: Prostate cancer antibody research programme - Immunex
Latest Information Update: 29 Jul 2002
Price : $50 *
At a glance
- Originator UroCor
- Developer Amgen; UroCor
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 29 Jul 2002 Immunex was acquired by, and merged into, Amgen.
- 11 Jul 2000 New profile
- 11 Jul 2000 Preclinical development for Prostate cancer in USA (Unknown route)